Nplate bone marrow stimulator approved to treat low platelet counts
FDA approved Amgen’s Nplate (romiplostim), the first product that directly stimulates the bone marrow to produce needed platelets in patients with a rare blood disorder ITP that can lead to serious bleeding. – The U.S. Food and Drug Administration approved Nplate (romiplostim), the first product that directly stimulates the bone marrow to produce needed platelets in patients with a rare blood disorder that can lead to serious bleeding.